Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives

In the past few decades, several gene mutations, including the anaplastic lymphoma kinase, epidermal growth factor receptor, ROS proto-oncogene 1 and rat sarcoma viral oncogene homolog (RAS), have been discovered in non-small cell lung cancer (NSCLC). Kirsten rat sarcoma viral oncogene homolog (KRAS...

Full description

Bibliographic Details
Main Authors:	Jia-Xin Li, Run-Ze Li, Lin-Rui Ma, Peng Wang, Dong-Han Xu, Jie Huang, Li-Qi Li, Ling Tang, Ying Xie, Elaine Lai-Han Leung, Pei-Yu Yan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-04-01
Series:	Frontiers in Pharmacology
Subjects:	non-small cell lung cancer KRAS covalent KRASG12C inhibitor immunotherapy natural compound combination treatment
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.875330/full

Similar Items

Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead
by: Hui-yu Li, et al.
Published: (2023-03-01)

Multiscale calculations reveal new insights into the reaction mechanism between KRASG12C and α, β-unsaturated carbonyl of covalent inhibitors
by: Xiao Yan, et al.
Published: (2024-12-01)

The research advances in Kirsten rat sarcoma viral oncogene homolog (KRAS)-related cancer during 2013 to 2022: a scientometric analysis
by: Yujie Huang, et al.
Published: (2024-04-01)

Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRASG12C inhibitor resistant tumors
by: Kai Wang, et al.
Published: (2024-12-01)

Naproxen inhibits spontaneous lung adenocarcinoma formation in KrasG12V mice
by: Gaurav Kumar, et al.
Published: (2021-06-01)

Establishing the mutational effect on the binding susceptibility of AMG510 to KRAS switch II binding pocket: Computational insights
by: Abdul Rashid Issahaku, et al.
Published: (2022-01-01)

Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report
by: Jeffrey Mathew Boby, et al.
Published: (2022-11-01)

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer
by: W. J. McDaid, et al.
Published: (2024-11-01)

The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers
by: Fernanda Andrade, et al.
Published: (2023-06-01)

Pancreatic HIF2α Stabilization Leads to Chronic Pancreatitis and Predisposes to Mucinous Cystic Neoplasm
by: Heather K. Schofield, et al.
Published: (2018-01-01)

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
by: Daolin Tang, et al.
Published: (2021-10-01)

Efficacy and toxicity of KRASG12C inhibitors in advanced solid tumors: a meta-analysis
by: Shoutao Dang, et al.
Published: (2024-07-01)

Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the United States
by: Ya-Ning Zhu, et al.
Published: (2024-06-01)

Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer
by: Ali Chour, et al.
Published: (2024-09-01)

Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation
by: Yu Li, et al.
Published: (2022-01-01)

Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis
by: Qi-An Chen, et al.
Published: (2024-02-01)

Establishing the Role of Iridoids as Potential Kirsten Rat Sarcoma Viral Oncogene Homolog G12C Inhibitors Using Molecular Docking; Molecular Docking Simulation; Molecular Mechanics Poisson–Boltzmann Surface Area; Frontier Molecular Orbital Theory; Molecular Electrostatic Potential; and Absorption, Distribution, Metabolism, Excretion, and Toxicity Analysis
by: Mubarak A. Alamri, et al.
Published: (2023-06-01)

Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer
by: Ofra Novoplansky, et al.
Published: (2024-11-01)

Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations
by: Meng Li, et al.
Published: (2019-11-01)

Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer
by: Liyuan Gao, et al.
Published: (2022-10-01)

Discovery of potent and noncovalent KRASG12D inhibitors: Structure-based virtual screening and biological evaluation
by: Yuting Wang, et al.
Published: (2022-12-01)

KRASG12C‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening
by: Constanza Tapia Contreras, et al.
Published: (2025-02-01)

MRTX1133 attenuates KRASG12D mutated-colorectal cancer progression through activating ferroptosis activity via METTL14/LINC02159/FOXC2 axis
by: Junwei Zou, et al.
Published: (2025-02-01)

Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis
by: Gu Xiaodong, et al.
Published: (2023-03-01)

Development of a biotin–streptavidin-enhanced enzyme-linked immunosorbent assay (BA-ELISA) for high-throughput screening of KRASG12C inhibitors
by: Shuang Liu, et al.
Published: (2022-03-01)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
by: Lixiu Peng, et al.
Published: (2023-01-01)

Rictor/mTORC2 signaling promotes proliferation and tumorigenicity of Kras mutant cancer cells
by: LAI Huiling, CHEN Shuqin
Published: (2025-01-01)

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
by: Gongmin Zhu, et al.
Published: (2021-11-01)

Association Between Patient Characteristics and Diet Profile with Kirsten rat sarcoma Kras and Neuroblastoma rat sarcoma (Nras) Gene Mutation in Colorectal Cancer
by: Dedy Indra Praja, et al.
Published: (2020-07-01)

Computer-aided drug design of some KRAS G12C inhibitors: Targeting the covalent and allosteric binding site for cancer therapy
by: Abdeen Tunde Ogunlana, et al.
Published: (2022-01-01)

In Silico Prediction of New Inhibitors for Kirsten Rat Sarcoma G12D Cancer Drug Target Using Machine Learning-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulation Approaches
by: Amar Ajmal, et al.
Published: (2024-04-01)

Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer
by: Gerhard Hamilton, et al.
Published: (2023-10-01)

Efficacy and Safety of KRASG12C Inhibitors in Advanced Solid Tumors with KRASG12C-mutated: A Single-arm Meta-analysis
by: TAN Dengxu, et al.
Published: (2023-07-01)

The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
by: Albert K. Kwan, et al.
Published: (2022-01-01)

Targeting KRAS mutant lung cancer: light at the end of the tunnel
by: Matthias Drosten, et al.
Published: (2022-03-01)

Kristen rat sarcoma virus (KRAS) G12F‐positive non‐small cell lung cancer mimicking KRAS G12C positivity: A case report
by: Issei Oi, et al.
Published: (2024-01-01)

Selective epithelial expression of KRASG12D in the Oncopig pancreas drives ductal proliferation and desmoplasia that is accompanied by an immune response
by: Carlos P. Jara, et al.
Published: (2025-02-01)

KSR induces RAS‐independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors
by: Guillem Paniagua, et al.
Published: (2022-09-01)

KRAS inhibitors: going noncovalent
by: Matthias Drosten, et al.
Published: (2022-12-01)

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
by: Sahar F. Bannoura, et al.
Published: (2022-11-01)